Skip to content

Study · Measured the body's own peptide · 2016

1 result

Humanin: a mitochondrial signaling peptide as a biomarker for impaired fasting glucose-related oxidative stress.

Voigt A, Jelinek HF

Physiological reports1 May 2016Cited by 38 (Europe PMC)

PMID27173674 (opens in a new tab)PMCIDPMC4873641 (opens in a new tab)DOI10.14814/phy2.12796 (opens in a new tab)PepBankPUB-27173674
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Mitochondrial RNR-2 (mt-RNR2, humanin) has been shown to play a role in protecting several types of cells and tissues from the effects of oxidative stress. Humanin (HN) functions through extracellular and intracellular pathways adjusting mitochondrial oxidative phosphorylation and ATP production. Addition of HN improved insulin sensitivity in animal models of diabetes mellitus but no clinical studies have been carried out to measure HN levels in humans associated with hyperglycemia. The plasma levels of HN in participants attending a diabetes complications screening clinic were measured. Clinical history and anthropometric data were obtained from all participants. Plasma levels of HN were measured by a commercial ELISA kit. All data were analyzed applying nonparametric statistics and general linear modeling to correct for age and gender. A significant decrease (P = 0.0001) in HN was observed in the impaired fasting glucose (IFG) group (n = 23; 204.84 ± 92.87 pg mL(-1)) compared to control (n = 58; 124.3 ± 83.91 pg mL(-1)) consistent with an adaptive cellular response by HN to a slight increase in BGL.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In adults attending a diabetes complications screening clinic, plasma humanin differed significantly (P = 0.0001) between the impaired fasting glucose group (204.84 ± 92.87 pg mL(-1)) and control (124.3 ± 83.91 pg mL(-1)); the abstract calls this a decrease, but the printed mean is higher in the impaired fasting glucose group.

    In plain wordsIn clinic adults, the body's own humanin levels differed in people with impaired fasting glucose versus controls. The abstract text and numbers disagree on direction.

    Peptide
    Humanin
    Outcome
    MixedPlasma humanin in impaired fasting glucose versus control
    Study

    n = 81

    Comparator
    Control group
    Outcome group
    Aging markers · Metabolic and weight

    Measurements

    Plasma humanin
    204.84 pg mL(-1)
    IFG group
    Plasma humanin
    124.3 pg mL(-1)
    control

    Source sentences

    Summary
    A significant decrease (P = 0.0001) in HN was observed in the impaired fasting glucose (IFG) group (n = 23; 204.84 ± 92.87 pg mL(-1)) compared to control (n = 58; 124.3 ± 83.91 pg mL(-1)) consistent with an adaptive cellular response by HN to a slight increase in BGL.
    1 context sentence
    Summary · context
    The plasma levels of HN in participants attending a diabetes complications screening clinic were measured.

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.